These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36908071)

  • 21. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
    Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
    Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HEREDITARY ANGIOEDEMA DUE TO C1-INHIBITOR DEFICIENCY IN PEDIATRIC PATIENTS IN CROATIA - FIRST NATIONAL STUDY, DIAGNOSTIC AND PROPHYLACTIC CHALLENGES.
    Karadža-Lapić L; Barešić M; Vrsalović R; Ivković-Jureković I; Sršen S; Prkačin I; Rijavec M; Cikojević D
    Acta Clin Croat; 2019 Mar; 58(1):139-146. PubMed ID: 31363336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bradykinin mediated gastrointestinal edema as a cause of abdominal attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.
    Obtulowicz P; Piotrowicz-Wojcik K; Dyga W; Stobiecki M; Popiela T; Obtulowicz K
    J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 36193964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C1-esterase inhibitor (Cinryze
    Gupta R; Balduzzi J; Davis-Lorton M
    Immunotherapy; 2018 Jun; 10(8):635-642. PubMed ID: 29569504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
    Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
    Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan.
    Ohsawa I; Honda D; Nagamachi S; Hisada A; Shimamoto M; Inoshita H; Mano S; Tomino Y
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):492-8. PubMed ID: 25872948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.
    Sinnathamby ES; Issa PP; Roberts L; Norwood H; Malone K; Vemulapalli H; Ahmadzadeh S; Cornett EM; Shekoohi S; Kaye AD
    Adv Ther; 2023 Mar; 40(3):814-827. PubMed ID: 36609679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management and prevention of hereditary angioedema attacks.
    Lumry WR
    Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hereditary and acquired angioedema.
    Patel G; Pongracic JA
    Allergy Asthma Proc; 2019 Nov; 40(6):441-445. PubMed ID: 31690390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 32. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.
    Bork K
    Immunotherapy; 2014; 6(5):533-51. PubMed ID: 24635050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
    Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
    Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor.
    Jones DH; Bansal P; Bernstein JA; Fatteh S; Harper J; Hsu FI; O'Connor M; Park N; Suez D
    World Allergy Organ J; 2022 Jan; 15(1):100621. PubMed ID: 35145604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current treatment of hereditary angioedema: An update on clinical studies.
    Banerji A
    Allergy Asthma Proc; 2010; 31(5):398-406. PubMed ID: 20929607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definition and classification of hereditary angioedema.
    Proper SP; Lavery WJ; Bernstein JA
    Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S03-S07. PubMed ID: 33109317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management.
    Bork K; Davis-Lorton M
    Eur Ann Allergy Clin Immunol; 2013 Feb; 45(1):7-16. PubMed ID: 23678554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert
    Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O
    Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
    West JB; Poarch K; Lumry WR
    Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.